Cardiac safety and efficacy of concomitant liposomal doxorubicin, docetaxel, and trastuzumab as neoadjuvant therapy in HER2-overexpressing breast cancer: A retrospective analysis.
Christine Brunner
No relevant relationships to disclose
Thomas Jaeger
No relevant relationships to disclose
Christoph Suppan
Other Remuneration - Roche
Elisabeth Mueller-Holzner
No relevant relationships to disclose
Zerina Jasarevic
No relevant relationships to disclose
Marija Balic
Other Remuneration - Roche
Georg Goebel
No relevant relationships to disclose
Christian Marth
No relevant relationships to disclose
Herbert Stoeger
Consultant or Advisory Role - Roche; Teva
Honoraria - Roche
Hellmut Samonigg
Consultant or Advisory Role - Teva
Honoraria - Roche
Michael Hubalek
Honoraria - Roche
Alois Lang
Honoraria - Roche